# Olive Leaf Extracts in the Control of Diabet

Study · id `cardio:ct-nct05605704` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05605704](<https://clinicaltrials.gov/study/NCT05605704>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05605704

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 500 participants.

## Technical summary

Registry record NCT05605704. Randomized; single masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2025-09-15 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 2/3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT05605704, source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)
- Started: 2023-01-01 (actual) (ClinicalTrials.gov record NCT05605704, source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)
- Primary completion: 2025-09-15 (anticipated) (ClinicalTrials.gov record NCT05605704, source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)
- Completion: 2025-12-15 (anticipated) (ClinicalTrials.gov record NCT05605704, source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)
- Countries: Tunisia (ClinicalTrials.gov record NCT05605704, source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05605704-2025-06-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Olive Leaf Extracts in the Control of Diabet
- Acronym: Dia-Athr
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Atherolive
- Intervention (Drug): Placebo Atherolive
- Lead sponsor: University of Monastir
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Monastir (`cardio:org-university-of-monastir`)

## Provenance

Content hash: 1cd0d1fc3efec0b64167a782ed7dfba1d0ab1010fada159fa1914b2890177fb3
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
